Mineralys Therapeutics, Inc. Common Stock (MLYS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mineralys Therapeutics, Inc. Common Stock (MLYS) has a cash flow conversion efficiency ratio of -0.059x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-32.56 Million) by net assets ($550.92 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Mineralys Therapeutics, Inc. Common Stoc market cap and net worth for the company's overall valuation and market capitalisation.
Mineralys Therapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Mineralys Therapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Mineralys Therapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mineralys Therapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. See cash flow to debt ratio of Mineralys Therapeutics, Inc. Common Stoc to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Coface SA
PA:COFA
|
0.021x |
|
LandBridge Company LLC
NYSE:LB
|
0.051x |
|
Zhuzhou Kibing Group Co Ltd
SHG:601636
|
0.047x |
|
SCHOTT Pharma AG & Co. KGaA
XETRA:1SXP
|
0.096x |
|
Tongyu Communication Inc
SHE:002792
|
0.032x |
|
Newell Brands Inc
NASDAQ:NWL
|
0.012x |
|
DO & CO Aktiengesellschaft
VI:DOC
|
0.150x |
|
NBT Bancorp Inc
NASDAQ:NBTB
|
0.042x |
Annual Cash Flow Conversion Efficiency for Mineralys Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual cash flow conversion efficiency of Mineralys Therapeutics, Inc. Common Stock from 2020 to 2025. View MLYS live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $646.69 Million | $-142.42 Million | -0.220x | +74.68% |
| 2024-12-31 | $191.26 Million | $-166.31 Million | -0.870x | -158.34% |
| 2023-12-31 | $241.15 Million | $-81.17 Million | -0.337x | -160.21% |
| 2022-12-31 | $-52.27 Million | $-29.22 Million | 0.559x | -11.97% |
| 2021-12-31 | $-22.93 Million | $-14.56 Million | 0.635x | -7.25% |
| 2020-12-31 | $-3.60 Million | $-2.46 Million | 0.685x | -- |
About Mineralys Therapeutics, Inc. Common Stock
Mineralys Therapeutics, Inc., a biopharmaceutical company, develops medicines to target diseases driven by dysregulated aldosterone in the United States. It is developing lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by dysregulated aldosterone, such as hypertension, chronic kidney disease, an… Read more